María C Ovejero-Benito1, Rocío Prieto-Pérez1, Mar Llamas-Velasco2, Ester Muñoz-Aceituno2, Alejandra Reolid2, Miriam Saiz-Rodríguez1, Carmen Belmonte1, Manuel Román1,3, Dolores Ochoa1,3, María Talegón1, Teresa Cabaleiro1, Esteban Daudén2, Francisco Abad-Santos1,3,4. 1. Department of Clinical Pharmacology, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), E28006, Madrid, Spain. 2. Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), E28006, Madrid, Spain. 3. SCReN Spanish Clinical Research Network, UICEC del Hospital de La Princesa; Servicio de Farmacología Clínica, E28006, Madrid, Spain. 4. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, E28029, Madrid, Spain.
Abstract
AIM: This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. MATERIALS & METHODS: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis. RESULTS: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. CONCLUSION: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
AIM: This study evaluated the influence of pharmacogenetics in psoriaticpatients treated with adalimumab and/or infliximab. MATERIALS & METHODS: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis. RESULTS: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. CONCLUSION: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
Authors: Ancor Sanz-Garcia; Alejandra Reolid; Laura H Fisas; Ester Muñoz-Aceituno; Mar Llamas-Velasco; Antonio Sahuquillo-Torralba; Rafael Botella-Estrada; Jorge García-Martínez; Raquel Navarro; Esteban Daudén; Francisco Abad-Santos; Maria C Ovejero-Benito Journal: Acta Derm Venereol Date: 2021-05-04 Impact factor: 3.875
Authors: Dmitry A Verbenko; Arfenya E Karamova; Olga G Artamonova; Dmitry G Deryabin; Alexander Rakitko; Alexandr Chernitsov; Anna Krasnenko; Artem Elmuratov; Victoria S Solomka; Alexey A Kubanov Journal: J Pers Med Date: 2020-12-29